Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chronvac-c
- Development stage
- Phase 2
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Chronvac-C is a therapeutic DNA vaccine developed for the treatment of chronic hepatitis C virus (HCV) infection. It is designed to stimulate the patient's immune system, particularly T-cell responses, against HCV by encoding non-structural proteins from the virus. Chronvac-C was developed as an alternative to direct-acting antivirals, aiming to induce long-lasting immunity and viral control in patients with chronic hepatitis C. The vaccine was investigated in early-phase clinical trials but has not advanced to late-stage development or approval.
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on chronvac-c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chronvac-c.